The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies

Abstract Psoriatic Arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis. Psoriasis (PsO) is a chronic, inflammatory skin disease, characterized by hyperproliferation and aberrant differentiation of keratinocytes. PsA and PsO can be considered as a unique disease and are im...

Full description

Saved in:
Bibliographic Details
Published in:Autoimmunity reviews 2014-01, Vol.13 (1), p.64-69
Main Authors: Novelli, Lucia, Chimenti, Maria Sole, Chiricozzi, Andrea, Perricone, Roberto
Format: Article
Language:English
Subjects:
Allergy and Immunology
IL-17
IL-23
Psoriasis
Psoriatic arthritis
Th17 cells
Therapeutic targets
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Psoriatic Arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis. Psoriasis (PsO) is a chronic, inflammatory skin disease, characterized by hyperproliferation and aberrant differentiation of keratinocytes. PsA and PsO can be considered as a unique disease and are immune-mediated diseases and both innate and adaptive immunity play a role in their pathogenesis. Initially, PsO and PsA were thought to be Th1-mediated diseases, however, in the last years, several studies have shown the role of interleukin 17 (IL-17) and Th17 cells in the pathogenesis of PsA and PsO. Th17 cells have been detected in dermal infiltrates of psoriatic lesions as well as in synovial fluid. Interleukin (IL)-23, produced by antigen presenting cells (APC), especially by dendritic cells (DC), is the key regulator cytokine for Th17 and IL-17 production. In this review we discuss the role of IL-17 and IL-23 in the pathogenesis of PsO and PsA and their role as therapeutic targets for PsO and PsA treatment.
ISSN:1568-9972
1568-9972
DOI:10.1016/j.autrev.2013.08.006